Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Futibatinib in FGFR aberrations
NCT04189445Phase 2Terminated
- Sponsor
- Taiho Oncology
- Start
- Aug 2020
- Primary completion
- Nov 2024
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 15
01
Overview
Phase 2, open-label trial of futibatinib in solid tumor, gastric cancer (GC), gastroesophageal junction cancer and 2 more (3 cohorts), sponsored by Taiho Oncology. Primary endpoints: Objective Response Rate and Complete Response Rate. Started Aug 2020; status: terminated.
02
Drugs
futibatinib
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction cancermyeloid neoplasmslymphocytic malignancy
Beyond the preview
Go deeper on NCT04189445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189445.